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INTRODUCTION
Up to 15% of the adult population 
experiences restless legs syn-
drome, or Ekbom syndrome dur-
ing their life [1]. The patients may 
present to a wide range of medi-
cal specialities such as general 
practitioners, general physicians, 
nephrologists, haematologists, 
obstetricians, endocrinologists, 
rheumatologists, and neurolo-
gists. 
Around 3% of patients experi-
ence major sleep disturbance 
that needs active medical treat-
ment [2,3]. Therefore, knowing 
about Restless Legs Syndrome 
(RLS) is vital to provide a proper 
diagnosis and treatment to pa-
tients with this condition.
DIAGNOSIS
The main symptoms of RLS are 
uncomfortable and unpleasant 
sensations in the legs. The diag-
nosis is a clinical one and based 
on the history. The following 
symptoms need to be identiﬁed 
[4,5]:
a) The urge to move the legs to 
relieve the uncomfortable and un-
pleasant sensations in the legs,
b) Symptoms get worse during 
periods of rest such as lying down 
or sitting,
c) Symptoms partially or totally 
relieved by movement such as 
walking,
d) Symptoms are worse during 
the evening and nighttime.    www.ljm.org.ly   
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The severity of the RLS could be 
determined by using The Interna-
tional RLS Study Group Rating 
Scale. This scale uses 10 items 
with ﬁve-response levels. It cov-
ers both the symptoms and their 
impact [6].
Periodic limb movements (PLM) 
have been linked to RLS. PLM are 
periodic and stereotypic move-
ments initially noted in sleep (pe-
riodic limb movements in sleep, 
PLMS). Each movement should 
last between 0.5-5 seconds with 
a frequency of one every 20-40 
seconds. Periodic limb move-
ment disorder (PLMD) has been 
attributed to the effects of the dis-
ruption of sleep by PLMS [7].
CAUSES
The majority of the cases of RLS 
are idiopathic. However, there 
are well known causes which are 
important to remember such as 
pregnancy, iron deﬁciency anae-
mia, renal failure, diabetes mel-
litus and hypothyroidism [8,9]. 
RLS might be more common in 
patients with Parkinson’s disease 
and Rheumatoid arthritis [8,9].
INVESTIGATIONS
Basic blood tests are needed in 
patients with RLS to exclude sec-
ondary causes. Full blood count 
including ferritin level, biochemi-
cal proﬁle, blood glucose, and 
thyroid function test are essen-
tial.
Sleep study or polysomnography 
are not needed to diagnose RLS 
except if there is uncertainty about 
the diagnosis or lack of response 
to the treatment [10]. However, 
polysomnography could be used 
to diagnosis PLM, mainly to de-
termine the number of PLM dur-
ing sleep [7].
TREATMENT
The following steps are important 
in treating patients with restless 
legs syndrome:
i) Any underlying causes, such as 
anaemia, have to be treated.
ii) A full explanation of RLS as 
well as reassurance are impor-
tant for the patients to cope with 
the condition.
iii) Non-pharmacological ap-
proaches can be useful such as 
keeping cool, avoiding caffeine 
before bed to improve sleep and 
taking regular exercise.
iv) Avoid wherever possible drugs 
that can aggravate the symptoms 
of RLS such as diuretics, tricyclic 
antidepressants, calcium antago-
nists and central nervous system 
stimulants.Libyan Journal of Medicine, Volume 1, 2006
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v) Patients with mild symptoms 
may not need drug treatment. 
However, levodopa was licensed 
for RLS in 2000 in both Germa-
ny and Switzerland. It is recom-
mended to be used in mild RLS 
and could be given on demand 
[11]. 
vi) Dopamine agonists are consid-
ered to be the treatment of choice 
for RLS. Recently, ropinirole and 
pramipexole have been licensed 
in the United Kingdom for treat-
ment of moderate to severe cas-
es. Both have been shown to be 
effective in double-blind place-
bo-controlled trials [12,13]. Rop-
inirole has been launched under 
a separate brand name Adar-
trel®. The dose is 0.25 for days 
1&2 to be increased to 0.5 mg for 
days 3 to 7. The dose could then 
be increased by 0.5 mg every 
week to 2.0 mg. The maximum 
recommended daily dose is 4 mg. 
The pramipexole starting dose is 
0.125 mg daily, which could be in-
creased after 4-7 days to 0.25 mg 
and then by 0.25 mg every week 
up to 0.75 mg. The dopamine ag-
onists should be taken 1-3 hours 
before bedtime.
vii) If patients do not respond or 
could not tolerate the dopamine 
agonists, then clonazepam and 
gabapentin could be used.   
viii) PLMD is usually treated simi-
larly to RLS.
CONCLUSION
Restless legs syndrome can be 
a disabling condition that is eas-
ily recognised clinically. Peri-
odic limb movements have been 
linked to RLS. Simple investiga-
tions are needed to exclude sec-
ondary causes and dopamine ag-
onists are now considered to be 
the treatment of choice.
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